Synsight

Synsight was a French biotech company, founded in 2013, that developed a proprietary AI-driven drug discovery platform, MT Bench. This platform focused on identifying small molecules targeting protein-RNA and protein-protein interactions, utilizing artificial intelligence, chemoinformatics, molecular modeling, and high-content cell imaging. The MT Bench technology, in-licensed from INSERM, was known for its unique capabilities in high-throughput screening for PPI and RNA interactions. Synsight operated preclinically, focusing on R&D partnerships and licensing models rather than internal clinical development. The company was acquired by Iktos in July 2024.